Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1685213rdf:typepubmed:Citationlld:pubmed
pubmed-article:1685213lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C1562368lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C1882534lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C0001857lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C1424272lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:1685213lifeskim:mentionsumls-concept:C2827664lld:lifeskim
pubmed-article:1685213pubmed:issue11lld:pubmed
pubmed-article:1685213pubmed:dateCreated1992-2-27lld:pubmed
pubmed-article:1685213pubmed:abstractTextA number of in vivo and in vitro results suggest that interferons have an antiretroviral effect on HIV. To check this, 15 HIV-positive patients who had no full-blown AIDS, were treated with recombinant interferon alpha 2b (5 mill. IU s. c. three times a week) over a period of six months. Twelve to 16 weeks after the initiation of treatment, an increase in CD 4 lymphocytes (+16%), NK cells (+16%), lymphocytes stimulation by con A (+ 176%), neopterin (+66%), and beta-2-microglobulin (+19%) was observed. By the end of the study, all these parameters had slightly decreased again. In all patients with CD4 lymphocytes greater than 0.2 c/nl, we observed a decrease in p24 antigen levels, but in patients with CD4 lymphocytes less than 0.2 c/nl, an increase. It would thus seem that any antiretroviral effect of IFN (as shown by the p24 antigen parameter) is more pronounced in patients with superior immune parameters.lld:pubmed
pubmed-article:1685213pubmed:languagegerlld:pubmed
pubmed-article:1685213pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1685213pubmed:citationSubsetIMlld:pubmed
pubmed-article:1685213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1685213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1685213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1685213pubmed:statusMEDLINElld:pubmed
pubmed-article:1685213pubmed:monthNovlld:pubmed
pubmed-article:1685213pubmed:issn0723-5003lld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:ArndtRRlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:NilssonMMlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:MeigelWWlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:LaufsRRlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:BaumannBBlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:FranklJJlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:PlettenbergAAlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:BahlmannWWlld:pubmed
pubmed-article:1685213pubmed:authorpubmed-author:StoehrAAlld:pubmed
pubmed-article:1685213pubmed:issnTypePrintlld:pubmed
pubmed-article:1685213pubmed:day15lld:pubmed
pubmed-article:1685213pubmed:volume86lld:pubmed
pubmed-article:1685213pubmed:ownerNLMlld:pubmed
pubmed-article:1685213pubmed:authorsCompleteYlld:pubmed
pubmed-article:1685213pubmed:pagination555-60, 606lld:pubmed
pubmed-article:1685213pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:meshHeadingpubmed-meshheading:1685213-...lld:pubmed
pubmed-article:1685213pubmed:year1991lld:pubmed
pubmed-article:1685213pubmed:articleTitle[Effect of alfa-2b interferon on prognostic parameters and clinical events in HIV positive patients in the LAS/ARC stage].lld:pubmed
pubmed-article:1685213pubmed:affiliationAbteilungen für Allgemeines Krankenhaus St. Georg, Hamburg.lld:pubmed
pubmed-article:1685213pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1685213pubmed:publicationTypeEnglish Abstractlld:pubmed